Device Trial Radar · NCT03988790
Evaluation of the Response to Monoclonal Antibody Therapy in Severe Asthma: Research of Predictive Biomarkers in Exhaled Air
Last checked: Nov 20, 2026Latest source record: Feb 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
50
Planned (sponsor's estimate)
Start
Dec 4, 2018
Primary completion
Dec 31, 2022
Study completion Dec 31, 2022
Sponsor
- Lead sponsor
- Hopital FochAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 17, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the change in the composition of Volatil Organic Compounds (VOC) in patients treated by monoclonal antibody for severe asthma.
Conditions
- Asthma
Interventions
VOC analysisDevice
VOC analysis in exhaled air with e-noses and mass spectrometry.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change of Volatil Organic Compound (VOC) profiles predictive of clinically significant responseTime frame: 1 day
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hôpital Foch
Suresnes, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.